NEW

Getinge Announces Medical Device Recall

Getinge has announced a global medical device recall related to specific Sevoflurane vaporizers for Flow Family Anesthesia systems. To date, no patient or operator adverse events have been reported. Getinge has reported to relevant authorities according to applicable...

Research: Medical Instrument Processing Personnel May Be Exposed to Tissue, Blood and Patient Fluids Despite PPE

“This pilot documented substantial splashing and droplet dispersal during manual cleaning of medical instruments, and personnel got wet even though they were wearing all the recommended PPE,”

New Scrubs Made of Bacteria-Killing Textile

Livinguard, a Swiss-based leader in self-disinfecting hygiene technology, has launched an apparel line of permanent self-disinfecting scrubs, underscrubs and lab coats utilizing its EPA-registered bacteria-killing textile. Livinguard scrubs, that continuously...

Finnish Startup Surgify Shares New Bone Cutting Technology

Finnish startup Surgify – that recently launched an all-new and innovative surgical technology that allows surgeons to perform surgical operations on bones faster and safer – has seen its first use cases on patients, according to a news release. The first surgeries...

BD Launches BD UltraSafe Plus 2.25 mL Passive Needle Guard

BD (Becton, Dickinson and Company) has launched the BD UltraSafe Plus 2.25 mL Passive Needle Guard for use by pharmaceutical companies in drug-device combination products. When combined with a Glass Prefillable Syringe, the BD UltraSafe Plus 2.25 mL system enables the subcutaneous delivery of biologic solutions of different fill volumes up to 2 mL and viscosities up to 30 cP.

BD UltraSafe Plus 2.25 mL is the latest solution to be commercially released into BD’s portfolio of drug delivery systems for combination products and is designed to meet the needs of health care providers, patients and caregivers in performing manual injections of biologic solutions. The unique design of BD UltraSafe Plus 2.25 mL complements bio-pharmaceutical companies’ combination product strategies – enabling patient-controlled injection for complex, high-viscosity drugs.

Biologic therapies are often self-administered by patients or caregivers and require delivery systems that provide ease of use and safety benefits for use in non-clinical settings. However, the viscosity and injection volume of biologics has shown a tendency to increase over the last years (>1 mL, >10 cP) that are beyond the capabilities of many commercialized injectable drug delivery systems. Biologic formulations with high volumes and viscosities often require stronger forces to inject, which can create challenges from a user’s perspective.

For more information, visit: https://drugdeliverysystems.bd.com/products/safety-and-shielding-systems/ultrasafe-plus-passive-needle-guard.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X